Damiano Librizzi

Damiano Librizzi

Auto-generated profile, based on publicly available information

Damiano Librizzi

Department of Nuclear Medicine, Protestant Hospital of Bethel Foundation, 33611 Bielefeld, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
FEFriederike Eilsberger
Friederike Eilsberger
AEAli Ebrahimifard
Ali Ebrahimifard
FSFlorian Torsten Spiegel
Florian Torsten Spiegel
Behrooz Hooshyar YousefiBehrooz Hooshyar Yousefi
Behrooz Hooshyar Yousefi
SBShamim Bagheri
Shamim Bagheri
DLDamiano Librizzi
Damiano Librizzi
Background/Objectives: The aim of this study was to demonstrate the importance of 68Gallium (68Ga)–prostate specific membrane antigen (PSMA)–positron emissions tomography (PET)/computed tomography (CT)(PET/CT) in prostate cancer patients for therapy management with individual analyses regarding the Gleason score, prostate specific antigen (PSA) value, and the risk groups defined by D’Amico. Methods: We retrospectively analyzed 562 68Ga-PSMA-11-PET/CT examinations performed from January 2015 to March 2023 at University Hospital Marburg. We assessed treatment changes post 68Ga-PSMA-11-PET/CT and categorized the cases based on PSA values, Gleason scores, and D’Amico risk groups. Results: In 415/562 (73.8%) of 68Ga-PSMA-11-PET/CT examinations, a modification in the therapy concept was recorded. Patients categorized as high risk or patients with Gleason scores of 7 through 10 or with PSA levels above 0.5 ng/mL (particularly within the ranges of 1.01–2 ng/mL, 3.01–5 ng/mL, and values exceeding 10 ng/mL) demonstrated a statistically significant association with treatment change. While no evidence of the disease was found most frequently in 38% of cases in the “Therapy continued without explicit reference” group, in the group with the adapted therapy, there was a considerable higher proportion of local tumors (19.2%) compared to the other groups (4.4% and 1.4%). Conclusions: Our results show the high impact of 68Ga-PSMA-PET/CT for patients with prostate cancer regarding therapy management planning, which is even more important for some patient groups.